Bristol Myers' legacy drug sales plunged 20% amid generic erosion and Medicare changes, spotlighting its shift to a newer ...

The State CET Cell, Maharashtra, has announced the registration schedule for the Additional MAH BCA/BBA/BMS/BBM CET 2025, following public requests for a re-exam. Registration runs from June 12 to ...

Objectives To develop a consensual definition for the term ‘early axial spondyloarthritis—axSpA’—and ‘early peripheral spondyloarthritis—pSpA’. Methods The ASAS (Assessment of SpondyloArthritis ...

MAH CET BCA/BBA/BMS/BBM result 2025: The State Common Entrance Test Cell, Maharashtra has officially declared the results of the MAH CET 2025 for BCA, BBA, BMS, and BBM programmes today, June 4 ...

Beyond the upfront payment, the deal calls for BMS to pay $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in milestone payments.

BMS will co-develop and co-commercialize BioNTech’s bispecific antibody BNT327 for solid tumors in a deal worth up to $11.1B for the German biotech.

BMS will pay an upfront cost of $1.5bn, as well as $2bn in non-contingent anniversary payments through 2028. In addition, BioNTech will be eligible to receive up to $7.6bn in development ...

The agreement, set against the backdrop of the ongoing 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, will mean BMS and BioNTech jointly share development and manufacturing costs on ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R ...

The news of BMS’ updated investment plan also comes shortly after the company let go of 516 workers in New Jersey. This is the third round of layoffs BMS has disclosed for Lawrenceville in 2025. This ...

Aficamten uses the same mechanism of action as Camzyos, meaning that there’s a chance BMS’ failure in the disease could “read through to the class,” William Blair analysts noted.

However, starring Naslen, Lukman Avaran, and Ganapathi S. Poduval, Khalid Rahman’s Alappuzha Gymkhana registered a ticket sale of 74K on BMS in advance. This is 13% higher than Mammootty’s film.